spacer
home > pmps > spring 2007 > excipients brace for a market transformation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Excipients Brace for a Market Transformation

The global excipients market faces challenges that may also turn out to be significant opportunities, explains Hans Huttinga of Kerry Bioscience – Sheffield Pharma Ingredients

The pharmaceutical excipient market is undergoing a period of intense change, driven by structural alterations in the drug market and the evolution of global business. Many challenges lie ahead, but also many opportunities. There are certainly bullish projections for growth. Frost & Sullivan placed the total European excipients market at $1.13 billion in 2004, and expects to see growth to $1.39 billion by 2008. The world market in 2004 was estimated to be worth around $2.5 billion (1).

This rosy financial future will, however, come at a cost. Over the next few years, excipient manufacturers will have to rise to the challenge of simultaneously servicing two very different markets: one valuing partnership and innovation, the other seeking competitive prices coupled with consistency of supply.

THE BLOCKBUSTERS’ DEMISE

For many years, big pharma companies have relied on ‘blockbuster’ drugs employing patented novel molecules. These were developed to treat the greatest number of people suffering from the most common diseases, and their huge development costs were more than offset by the promise of high sales. At the 2006 Drug Discovery Conference, held in Boston, it was estimated that the cost of producing a successful new drug could now exceed $2 billion (2).

However, with effective patent lives of only around 10 years, increased pressure from HMOs to cut prescription costs, and ever more onerous regulation, blockbusters are increasingly under threat from low-cost generic medication. Cutting Edge Information has estimated that by 2008, over $80 billion worth of blockbusters’ patents will have expired, potentially wiping 80 per cent from established manufacturers’ market share (2). Drug companies are beginning to realise that they must adopt a new business model in which drugs are increasingly marketed to specialist treatment niches, positioned not as ‘me too’ but differentiator products, taking into account consumer preference factors such as appearance, ease of use and novel functionality.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Hans Huttinga is the Strategic Marketing Director (Pharma Ingredients) of Kerry Bioscience – Sheffield Pharma Ingredients. Hans, who has worked for the Kerry Bioscience organisation since 2000, has accrued more than 15 years of experience in new business, commercialisation and development of highlyvalued pharmaceutical ingredients and life science products within the life science and pharma markets. He graduated as an Engineer in Biotechnology in 1989, and has a long track record in business creation, sales and marketing within profitable companies serving the excipient and cell nutrition markets, and supplying the pharmaceutical and biotechnology industries.
spacer
Hans Huttinga
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement